VRB-103 oral-amylin Phase 1 results
Verdiva’s current news/pipeline reports July 2026 Phase 1 initiation for VRB-103, a selective oral amylin peptide with weekly-dosing potential. Human results differ from September’s preclinical presentation.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Current private investment classification is explicitly supported by investor RA Capital; recheck before activation.
- Primary source reports trial initiation, not a precise data-release date or proven once-weekly clinical efficacy.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Phase 1 readout — date unconfirmed
Company context
An official company source identifies the company as privately held. This is source-reported context, not independent legal-registry verification; recheck ownership, listing and acquisition status before any market listing.
Potential outcome market
Will Verdiva publicly report human safety and pharmacokinetic data for oral VRB-103 by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.